{{Drugbox
| IUPAC_name = 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-carboxamide
| image = 5F-PCN_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number =None <!-- as of 20/nov/15 -->
| ATC_prefix = 
| ATC_suffix =  
| PubChem = 
|  ChemSpiderID = 34450856
| smiles            = O=C(NC1=C(C=CC=C2)C2=CC=C1)C3=CN(CCCCCF)C4=C3C=NC=C4
| StdInChI          = 1S/C23H22FN3O/c24-12-4-1-5-14-27-16-20(19-15-25-13-11-22(19)27)23(28)26-21-10-6-8-17-7-2-3-9-18(17)21/h2-3,6-11,13,15-16H,1,4-5,12,14H2,(H,26,28)
| StdInChIKey       = BRRZRRZUERBDQL-UHFFFAOYSA-N

<!--Chemical data-->
| C=23 | H=22 | F=1 | N=3 | O=1
| molecular_weight =  	375.4 g/mol
}}

'''5F-PCN''' (also known as '''5-F-MN-21''') is an azaindole-based [[synthetic cannabinoid]] that is presumed to be a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/15963 | title=5F-PCN | publisher=Cayman Chemical | accessdate=22 July 2015}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S022352341100612X | title=Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity | author=Antoni R. Blaazer | journal=European Journal of Medicinal Chemistry |date=October 2011  | volume=46 | issue=10 | pages=5086–5098 | doi=10.1016/j.ejmech.2011.08.021 | pmid=21885167|display-authors=etal}}</ref> It is closely related to [[NNE1]]. Given the known metabolic liberation (and presence as an impurity) of [[amantadine]] in the related compound [[APINACA]], it is suspected that metabolic hydrolysis of the amide group of 5F-PCN may release [[1-naphthylamine]], a known [[carcinogen]].

== Legal status==

Sweden's public health agency suggested to classify 5F-PCN as hazardous substance on November 10, 2014.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | publisher=Folkhälsomyndigheten | accessdate=22 July 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-NNE1]]
* [[AM-2201]]
* [[APICA (synthetic cannabinoid drug)|APICA]]
* [[CUMYL-PICA]]
* [[JWH-018]]
* [[NM-2201]]
* [[SDB-005]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Naphthoylindoles]]
[[Category:Indolecarboxamides]]
[[Category:Pyrrolopyridines]]
[[Category:Fluoroalkanes]]

{{cannabinoid-stub}}